financetom
Business
financetom
/
Business
/
Mattel recalls Fisher-Price Snuga infant swings on suffocation risks after five deaths
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Mattel recalls Fisher-Price Snuga infant swings on suffocation risks after five deaths
Oct 10, 2024 11:18 PM

(Reuters) - Mattel ( MAT ) is recalling all models of its Fisher-Price Snuga infant swings after five deaths were reported from suffocation hazards between 2012 and 2022, the U.S. consumer protection authority and the toymaker said on Thursday.

The Snuga Swing, targeted at infants of up to nine months of age, has both front-to-back and side-to-side motions and comes in 21 different models.

The Consumer Product Safety Commission (CPSC) said the swing should never be used for sleep and bedding materials such as blankets should not be added to it as they could increase the risk of suffocation.

"Consumers should immediately remove both the headrest, by cutting the tether, and the body support insert from the seat pad before continuing to use the swing," the CPSC warned.

Fisher-Price would provide a partial refund of $25 to consumers who do so, the statement said.

"The recall was to repair, not a full product recall," Mattel ( MAT ) said.

The five reported deaths were in the age group of one to three months, when the product was used for sleep and bedding materials were added.

The swings were sold for about $160 at stores such as Toys R Us, Walmart's Sam's Club and Target as well as Amazon ( AMZN ).

About 2.1 million swings were sold in the United States, about 99,000 swings were sold in Canada and about 500 swings were sold in Mexico since 2010, according to the statement.

The products are being jointly recalled by the U.S. CPSC, Health Canada and Mexico's Consumer Protection Federal Agency.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Trump's Tariffs Announcement 'Worse Than the Worst Case Scenario,' Wedbush Says
Trump's Tariffs Announcement 'Worse Than the Worst Case Scenario,' Wedbush Says
Apr 3, 2025
04:35 AM EDT, 04/03/2025 (MT Newswires) -- The slate of tariffs from the Trump administration is worse than the worst case scenario feared by analysts, according to Wedbush Securities. In a note emailed to clients on Wednesday, Wedbush analysts, led by Daniel Ives, said tech stocks will be under major pressure following the announcement. On Wednesday, the Trump administration unveiled...
Novartis Gets FDA Accelerated Approval for Vanrafia
Novartis Gets FDA Accelerated Approval for Vanrafia
Apr 3, 2025
04:41 AM EDT, 04/03/2025 (MT Newswires) -- Novartis ( NVS ) said late Wednesday the US Food and Drug Administration granted accelerated approval for Vanrafia to reduce proteinuria in adults with primary immunoglobulin A nephropathy, or IgAN, at risk of rapid disease progression. IgAN is a progressive, rare kidney disease. Data from an ongoing phase III showed that Vanrafia achieved...
Traders seek refuge in Aussie consumer staples as US tariffs spark market fall
Traders seek refuge in Aussie consumer staples as US tariffs spark market fall
Apr 3, 2025
By Rajasik Mukherjee (Reuters) - Shares of Australia's consumer staple companies rose on Thursday, driven by grocers Coles and Woolworths, as investors moved to safer bets after U.S. President Donald Trump's reciprocal tariffs sparked global market turmoil. Shares of the sector ended 1.3% higher while the broader Australian market fell 0.9% to its lowest since March 14. Coles rose 2.1%...
Mesoblast Files Meeting Request With FDA for Ischemic Heart Failure Treatment Candidate
Mesoblast Files Meeting Request With FDA for Ischemic Heart Failure Treatment Candidate
Apr 3, 2025
04:23 AM EDT, 04/03/2025 (MT Newswires) -- Mesoblast (MESO) said late Wednesday it expets to have a type B meeting with the US Food and Drug Administration during the current quarter to discuss the accelerated approval pathway for ischemic heart failure treatment candidate, Revascor. The main goals of the meeting are to get FDA feedback on relevant chemistry, manufacturing &...
Copyright 2023-2025 - www.financetom.com All Rights Reserved